TG Therapeutics, Inc.
Clinical trials sponsored by TG Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing treatments for B-cell malignancies and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study checks how much MS drug gets into breast milk Results expected Oct 2026 (estimated)
- MS patients may soon get a shot instead of an IV drip Results expected Oct 2026 (estimated) May already have reported ↗
- Could a single infusion of modified immune cells tame autoimmune attacks? Results expected Dec 2026 (estimated)
- New dosing strategy for MS drug ublituximab under study in 800-Patient trial Results expected Jan 2027 (estimated) May already have reported ↗
- MS drug delivery showdown: belly vs. thigh, pen vs. syringe Results expected Jul 2027 (estimated) May already have reported ↗
-
MS patients may soon get a shot instead of an IV drip
Disease control OngoingThis phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety…
Phase 3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
Ublituximab shows promise for Long-Term MS control in large extension trial
Disease control OngoingThis study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…
Phase 3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC